Oncology Corporate Profile
AbbVie is a global, research-based biopharmaceutical company formed in 2013 following separation from Abbott Laboratories. The company's mission is to use its expertise, dedicated people and unique approach to innovation to develop and market advanced therapies that address some of the world's most complex and serious diseases. Together with its wholly-owned subsidiary, Pharmacyclics, AbbVie employs more than 28,000 people worldwide and markets medicines in more than 170 countries.
|EMPLICITI_?||elotuzumab||EMPLICITI is a SLAMF7-directed immunostimulatory antibody indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received one to three prior therapies|
|IMBRUVICA??||ibrutinib||IMBRUVICA is a kinase inhibitor indicated for the treatment of patients with: |
_??Mantle cell lymphoma (MCL) who have received at least one prior therapy.
Accelerated approval was granted for this indication based on overall response rate. Continued approval for this indication may be contingent upon verification of clinical benefit in confirmatory trials.
_??Chronic lymphocytic leukemia (CLL)
_??Chronic lymphocytic leukemia with 17p deletion.
|VENCLEXTA_?||venetoclax||VENCLEXTA is a BCL-2 inhibitor indicated for the treatment of patients with chronic lymphocytic leukemia (CLL) with 17p deletion, as detected by an FDA approved test, who have received at least one prior therapy. |
This indication is approved under accelerated approval based on overall response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.
View additional information on commercial products here »
|Brand / Product||Class||Area of Study||Phase||Partnership|
|elotuzumab (+ lenalidimide and dexamethasone) / Huluc63||anti-CS1 monoclonal antibody (humanized)||2nd line metastatic Multiple Myeloma||III||Bristol-Myers Squibb|
|veliparib / ABT-888||PARP inhibitor||BRCA Breast cancer||III|
|veliparib / ABT-888||PARP inhibitor||Non Small Cell Lung Cancer (NSCLC)||III|
|veliparib / ABT-888||PARP inhibitor||Ovarian cancer||III|
|veliparib / ABT-888||PARP inhibitor||squamous Non Small Cell Lung Cancer (NSCLC)||III|
|veliparib / ABT-888||PARP inhibitor||Triple negative Breast cancer||III|
|Empliciti / elotuzumab||monoclonal antibody||1st line Multiple Myeloma||III|
|Imbruvica_ / ibrutinib||Bruton's tyrosine kinase (BTK) inhibitor||Diffuse Large B-Cell Lymphoma (DLBCL)||III|
|Imbruvica_ / ibrutinib||Bruton's tyrosine kinase (BTK) inhibitor||Follicular Lymphoma (FL)||III|
|Imbruvica_ / ibrutinib||Bruton's tyrosine kinase (BTK) inhibitor||Multiple Myeloma||III|
|Imbruvica_ / ibrutinib||Bruton's tyrosine kinase (BTK) inhibitor||Pancreatic cancer||III|
|Venclexta / ABT-199||Bcl-2 inhibitor||1st line Chronic Lymphocytic Leukemia (CLL)||III|
|Venclexta / ABT-199||Bcl-2 inhibitor||Acute Myelogenous Leukemia (AML)||III|
|Venclexta / ABT-199||Bcl-2 inhibitor||Multiple Myeloma||III|
|Venclexta / ABT-199||Bcl-2 inhibitor||Relapsed refractory Chronic Lymphocytic Leukemia (CLL)||III|
|Imbruvica_ / ibrutinib||Bruton's tyrosine kinase (BTK) inhibitor||Acute Myelogenous Leukemia (AML)||II|
|Imbruvica_ / ibrutinib||Bruton's tyrosine kinase (BTK) inhibitor||Various cancer types||II|
|Rova-T / rovalpituzumab tesirine (+nivolumab and ipilimumab)||antibody drug conjugate||Small Cell Lung Cancer (SCLC)||II||Bristol-Myers Squibb|
|Venclexta / ABT-199||Bcl-2 inhibitor||Diffuse Large B-Cell Lymphoma (DLBCL)||II|
|Venclexta / ABT-199||Bcl-2 inhibitor||Follicular Lymphoma (FL)||II|
|ABBV-075||small molecule Bromodomain and Extra-Terminal motif (BET) inhibitor||Acute Myelogenous Leukemia (AML)||I|
|ABBV-075||small molecule Bromodomain and Extra-Terminal motif (BET) inhibitor||Multiple Myeloma||I|
|ABBV-838||antibody drug conjugate||Multiple Myeloma||I|
|ABBV-075||small molecule Bromodomain and Extra-Terminal motif (BET) inhibitor||Various cancer types||I|
|ABBV-085||antibody drug conjugate||Various cancer types||I|
|ABBV-339||antibody drug conjugate||Various cancer types||I|
|ABBV-221||antibody drug conjugate||Various cancer types||I|
|ABT-165||Dual variable domain immunoglobulin (DVD)||Various cancer types||I|
|Rova-T / rovalpituzumab tesirine||antibody drug conjugate||Neuroendocrine tumor||I|
View additional information on product candidates here »
3/28/2017 11:00 am
3/27/2017 09:04 pm
3/27/2017 05:03 pm
3/27/2017 12:04 pm
3/26/2017 03:00 pm
3/25/2017 06:00 pm
3/25/2017 02:01 pm
3/24/2017 03:02 pm
3/23/2017 11:04 am
[PR Newswire] - NORTH CHICAGO, Ill., March 23, 2017 /PRNewswire/ -- AbbVie, a global biopharmaceutical company, today announced that actress, dancer and Emmy Award-winning choreographer Julianne Hough is helping to raise awareness about endometriosis through a campaign called "Get in the Know about ME in EndoMEtriosis." The campaign, sponsored by AbbVie, is dedicated to inspiring women to learn about and understand endometriosis, a disease affecting an estimated one in 10 women,1 and to address their symptoms with a healthcare professional. Despite being one of the most common gynecologic disorders in America, there is a lack of awareness and prioritization of endometriosis as an important women's health issue.
3/23/2017 04:05 am
3/22/2017 09:02 pm
3/22/2017 05:03 pm
3/22/2017 05:01 pm
3/22/2017 12:01 pm
[Accesswire] - Upcoming AWS Coverage on AbbVie LONDON, UK / ACCESSWIRE / March 22, 2017 / Active Wall St. blog coverage looks at the headline from US drugmaker Eli Lilly and Co. (NYSE: LLY ) as the Company announced ...
3/21/2017 11:05 am
3/21/2017 11:00 am
3/20/2017 11:01 pm
3/20/2017 01:03 pm
[Accesswire] - SAN DIEGO, CA / ACCESSWIRE / March 20, 2017 / The Shareholders Foundation, Inc. announces that a lawsuit is pending in Illinois on behalf of certain purchasers of (NYSE: ABBV) shares over alleged Securities ...
3/15/2017 09:04 pm
3/15/2017 01:02 pm
3/14/2017 08:04 pm
3/14/2017 12:00 pm
[PR Newswire] - NORTH CHICAGO, Ill., March 14, 2017 /PRNewswire/ -- AbbVie (ABBV), a global biopharmaceutical company, today announced that priority review has been granted by the Japanese Ministry of Health, Labour and Welfare (MHLW) for its investigational, pan-genotypic, ribavirin-free regimen of glecaprevir/pibrentasvir (G/P) for the treatment of all major genotypes (GT1-6) of the chronic hepatitis C virus (HCV). This priority review follows European Medicines Agency (EMA) accelerated assessment and U.S. Food and Drug Administration (FDA) priority review designations in December 2016 and January 2017 respectively.
3/14/2017 12:00 pm
3/13/2017 10:05 pm